Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
9 hedge funds and large institutions have $15.9M invested in Celyad Oncology SA American Depositary Shares in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
10% less funds holding
Funds holding: 10 → 9 (-1)
22% less capital invested
Capital invested by funds: $20.4M → $15.9M (-$4.59M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$439K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$64.5K |
| 3 |
Renaissance Technologies
New York
|
+$54.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$17.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$760K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.82K |
| 3 |
II
Inspire Investing
Meridian,
Idaho
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Victory Capital Management
San Antonio,
Texas
| $14.6M | -$760K | -18,280 | -4% |
|
|
2
Jane Street
New York
| $586K | +$439K | +10,562 | +169% |
|
|
3
Renaissance Technologies
New York
| $230K | +$54.1K | +1,300 | +25% |
|
4
Morgan Stanley
New York
| $211K | – | – | – |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $173K | +$64.5K | +1,551 | +44% |
|
|
6
UBS Group
Zurich,
Switzerland
| $50K | +$17.8K | +427 | +41% |
|
7
Bank of Montreal
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
8
Zurich Cantonal Bank
Zurich,
Switzerland
| $3K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $1K | -$4.82K | -116 | -78% |
|
|
II
10
Inspire Investing
Meridian,
Idaho
| – | -$1K | -21 | Closed |
|
CYAD Hedge Fund Activity: Q1 2018 in Review
9 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q1 2018, worth a combined $15.9M — down 22% from $20.4M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CYAD and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 4 added.
The largest buyer was Jane Street, adding an estimated $439K. The largest seller was Victory Capital Management, cutting an estimated $760K.
- 9 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q1 2018, down from 10 in Q4 2017.
- Funds reported $15.9M of Celyad Oncology SA American Depositary Shares stock for Q1 2018, down 22% quarter-over-quarter.
- 0 funds opened new Celyad Oncology SA American Depositary Shares positions in Q1 2018 and 1 closed out, a net change of -1 holder.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q1 2018 was Jane Street, an estimated $439K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q1 2018 was Victory Capital Management, an estimated $760K sold.
Based on aggregated 13F filings for Q1 2018.